Level Biotechnology Inc.

Level Biotechnology Inc.

TTPEX:3118
29.95
TWD
-0.15
(-0.50%)
1.98EPS
15.75P/E
1.02BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
16.3
16.43
16.02
15.82
17.8
19.38
19.69
20.72
20.87
18.27
20.36
22.54
22.7
21.4
Basic EPS, GAAP
1.99
2.37
2.42
1.95
2.11
1.2
1.46
1.79
2.1
1.8
1.94
2
2.46
1.99
Free Cash Flow per Basic Share
2.84
2.99
2.76
2.16
1.86
0.75
3.28
2.49
4.52
1.8
1.93
-4.92
0.83
2.7
Dividend per Share
1.7
1.7
2
2.2
1.9
1.9
1
1.3
1.6
1.9
1.7
1.7
1.8
- -
Book Value per Share
15.05
15.71
16.17
15.88
16.09
15.37
15.83
16.31
16.79
16.71
16.93
17.25
17.88
17.1
Tangible Book Value per Share
15.04
15.7
16.16
15.88
16.09
15.37
15.83
16.31
16.79
16.71
16.93
17.25
17.88
17.1
Basic Weighted Avg Shares
32
32
32
32
32
32
32
32
32
32
32
32
32
32
Sales/Revenue/Turnover
529
533
520
514
578
629
639
672
677
593
661
731
737
695
Operating Margin (%)
14.13
16.63
16.44
14.51
13.99
7.82
8.83
9.84
11.66
10.94
10.26
10.29
11.34
9.82
Depreciation Expense
14
14
15
14
15
16
20
21
20
20
20
21
22
24
Net Income, GAAP
65
77
78
63
68
39
47
58
68
58
63
65
80
65
Effective Tax Rate (%)
16.53
16.13
17.54
17.25
17.81
21.03
20.17
19.99
19.69
20.08
20.02
20.11
18.32
19.12
Profit Margin (%)
12.21
14.41
15.08
12.32
11.83
6.19
7.42
8.63
10.07
9.86
9.52
8.86
10.82
9.28
Working Capital
297
328
349
343
341
325
353
384
409
411
428
231
225
220
LT Debt
- -
- -
- -
- -
- -
- -
15
13
11
10
10
8
4
3
Total Equity
488
510
525
515
522
499
514
529
545
542
549
560
580
555
Return on Invested Capital (%)
12.7
14.62
13.38
11.57
12.06
7.49
8.64
9.68
11.29
9.19
9.54
10.44
11.58
9.65
Return on Capital (%)
13.29
15.36
15.13
12.14
13.13
7.61
9.27
10.85
12.41
10.55
11.3
11.45
13.76
11.38
Return on Common Equity (%)
13.35
15.39
15.16
12.16
13.17
7.62
9.36
11.13
12.69
10.75
11.52
11.68
13.98
11.55

Capital Structure

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
5
5
7
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
1,073
1,032
1,016

Working Capital

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
475
451
460
Cash, Cash Equivalents & STI
223
195
202
Accounts Receivable, Net
125
110
125
Inventories
108
129
117
Total Current Liabilities
225
249
240
Payables & Accruals
- -
- -
- -
ST Debt
5
5
7
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.04%
1.86%
3.62%
Free Cash Flow
-22.34%
-88.63%
-116.88%
Net Income, GAAP
2.67%
7.36%
22.97%
Sales/Revenue/Turnover
3.81%
2.22%
0.72%
Total Cash Common Dividend
- -
- -
5.88%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
178
166
182
205
731
2025
177
172
200
188
737
2026
159
162
186
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.59
0.35
0.46
0.6
2
2025
0.61
0.45
0.83
0.57
2.46
2026
0.53
0.42
0.47
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.07
1.7
2025
- -
- -
- -
- -
1.8
2026
- -
- -
- -
- -
- -

Company Description

CEO
Chun Lung Chiu
Full Time Employees
128
Sector
Distribution services
Industry
Medical distributors
Address
No. 80, Kangning Street New Taipei TP Taiwan 221
IPO Date
Sep 10, 2004
Business
Level Biotechnology Inc. engages primarily in the marketing and distribution of biomedical products and the provision of preclinical contract research organization (CRO) services. Its main product portfolio includes cell culture products; immunology reagents; molecular biology products; biomedical precision instruments and equipment; and laboratory consumables and reagents. The company operates preclinical testing services covering mammalian toxicology, genetic toxicology, pharmacology, biocompatibility, and model animal production. These offerings target biotech, pharmaceutical, medical device, animal health, and agrichemical industries. Founded in 1989 and headquartered in New Taipei City, Taiwan, Level Biotechnology has established a reputed presence in Taiwan and maintains partnerships with international suppliers such as Corning Life Science, Biochrom AG, Millipore-Chemicon, and others. In recent years, Level Biotechnology has expanded its CRO services significantly, focusing on preclinical services for new chemical entities (NCE), biopharmaceutics, and medical devices, enhancing its service quality certified under ISO9001:2000. The company reported ongoing revenue growth and improved net income performance through 2025, reflecting operational enhancements and market expansion. Level Biotechnology emphasizes a one-stop-shop model for preclinical research, streamlining regulatory toxicology, customized study designs, and disease models for clients globally. There have been no major announced mergers or acquisitions, but the company continues to bolster its service portfolio and operational capabilities to support evolving biomedical research and development needs in its markets. Level Biotechnology operates extensively within Taiwan and internationally through its CRO services, providing comprehensive biomedical research support alongside its distribution business. The firm’s integration of product distribution with specialized preclinical services positions it as a significant player in biotechnology research, development, and supply chains in the Asia-Pacific region. The company’s strategic focus remains on expanding service depth and fostering strong client relationships across biomedical sectors while maintaining competitive product offerings sourced from leading global brands. This combined approach enables Level Biotechnology to address diversified market demands in biomedical science and technology development.